SAUZULLO, Ilaria
 Distribuzione geografica
Continente #
NA - Nord America 2.684
EU - Europa 763
AS - Asia 626
SA - Sud America 47
AF - Africa 7
OC - Oceania 3
Totale 4.130
Nazione #
US - Stati Uniti d'America 2.651
SG - Singapore 261
IN - India 206
IT - Italia 204
CN - Cina 145
SE - Svezia 129
FI - Finlandia 105
UA - Ucraina 105
RU - Federazione Russa 83
DE - Germania 46
AR - Argentina 43
CA - Canada 25
IE - Irlanda 22
GB - Regno Unito 20
BG - Bulgaria 17
BE - Belgio 9
NL - Olanda 9
BZ - Belize 5
TG - Togo 5
BR - Brasile 4
HK - Hong Kong 4
ID - Indonesia 4
MY - Malesia 4
RO - Romania 4
AU - Australia 3
CH - Svizzera 3
MX - Messico 3
AT - Austria 2
FR - Francia 2
PL - Polonia 2
ZA - Sudafrica 2
CZ - Repubblica Ceca 1
IR - Iran 1
TR - Turchia 1
Totale 4.130
Città #
Fairfield 310
Chandler 295
Dearborn 200
Ashburn 183
Singapore 171
Woodbridge 140
Wilmington 117
Seattle 103
Ann Arbor 102
Princeton 101
Plano 97
Fremont 94
Houston 91
Cambridge 73
Rome 73
Beijing 62
Boston 48
Federal 43
Millbury 41
San Paolo di Civitate 38
Jacksonville 34
Andover 33
San Diego 32
Lawrence 31
Norwalk 29
Moscow 28
Falls Church 25
Santa Clara 23
Dublin 21
Boardman 17
Sofia 17
Washington 15
Milan 13
Ottawa 13
Hefei 12
Yubileyny 11
Nuremberg 10
Toronto 10
Brussels 9
Helsinki 9
Des Moines 8
Nanjing 8
San Jose 8
Prato 7
Dallas 6
Falkenstein 6
San Mateo 6
Belize City 5
Kunming 5
Lomé 5
Mannheim 5
Monterotondo 5
Pune 5
Shenyang 5
St Petersburg 5
Grafing 4
Hong Kong 4
Jakarta 4
Modena 4
Nanchang 4
Naples 4
Bern 3
Bühl 3
Guangzhou 3
Hebei 3
Indiana 3
Jinan 3
London 3
Munich 3
New York 3
Phoenix 3
Pozzuoli 3
Saint Louis 3
Sassoferrato 3
Wuhan 3
Amsterdam 2
Aprilia 2
Arezzo 2
Atlanta 2
Baotou 2
Buffalo 2
Catanzaro 2
Chengdu 2
Chicago 2
Chongqing 2
Columbus 2
Fasano 2
Fuzhou 2
Guanzate 2
Laurel 2
Mexico City 2
Prineville 2
Provo 2
Quzhou 2
Shanghai 2
São Paulo 2
Vienna 2
Warsaw 2
Xian 2
Arnsberg 1
Totale 2.978
Nome #
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. 106
Multifunctional analysis of CD4+T-cell response as immune-based model for tuberculosis detection 101
Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy 96
Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of Mycobacterium tuberculosis 92
Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases 83
Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases 80
The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature 77
QTF-Gold assay for monitoring of anti-tuberculosis therapy in subjects with active TB 76
Antiviral immune response in patients with multiple sclerosis, healthy siblings and twins 75
Detecting latent tuberculosis in compromised patients 74
Diagnostic accuracy of Xpert MTB/RIF versus smear microscopy in the early diagnosis of tuberculosis in the real life of the “Umberto I” Hospital in Rome 74
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells 73
Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection 71
Role of interferon-gamma release assays (IGRAs) for the screening of latent tuberculosis infection in patients candidates for TNF-α antagonist 69
Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc 68
Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. 67
Effetto in vitro ed ex vivo dei farmaci antitubercolari sul rilascio di IFN-gamma 66
Rapida diagnosi di infezione da Mycobatteri atipici: utilizzo dei kit Arnika su campioni respiratori 64
Long-term IFN-γ and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results 63
Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4(+) T cells 63
Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count. 62
Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. 61
Influence of previous tuberculin skin test on serial IFN-γ release assays 61
QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis 60
HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition 59
Multifunctional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with TNF antagonists. 58
DIVERGENT ROLE FOR DENDRITIC CELLS IN VIRAL CONTROL AND CHRONIC INFLAMMATION IN HIV DISEASE 56
Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc 54
Comparison of the effects of air-powder abrasion, chemical decontamination, or their combination in open-flap surface decontamination of implants failed for peri-implantitis: an ex vivo study 54
ROLE OF INTERFERON-Gamma RELEASE ASSAYS (IGRAS) IN HIV-SSOCIATED TUBERCULOSIS: IN VITRO AND IN VIVO EFFECT OF ANTITUBERCULOUS DRUGS 53
In vivo and in vitro effects of antituberculosis treatment on mycobacterial Interferon-gamma T cell response. 51
Study of the genotypic-resistant pattern in plasma of a group of HIV-infected Cameroonian pregnant women and children 50
Diagnostic accuracy of Xpert MTB/RIF versus smear microscopy in the early diagnosis of tuberculosis in the real life of the “Umberto I” Hospital in Rome. 50
Diminuzione delle cellule dendritiche del sangue periferico in corso di infezione da HIV: ruolo dell’apoptosi 49
“CCR5 antagonist maraviroc blocks the migration of circulating mature dendritic cells and macrophage in vitro: potential role on HIV-associated inflammation” 49
"Cellule dendritiche del sangue periferico nel monitoraggio del paziente con infezione da HIV". 48
“CXCL10/IP10: biomarker alternativo nella diagnosi dell’infezione tubercolare” 47
FIVE YEARS (2003-2008) OF MINGHA (MY CHILD) PROJECT IN A RURAL AREA OF WEST CAMEROON: IS THE TIME FOR AN AIDS-FREE NEW GENERATION? 46
"Interferon-g Release Assays (IGRAs) for Detection and Treatment Response of Tuberculosis in Patients with HIV Infection" 45
Detection of IL-2 in addition to IFN-gamma discriminates active tuberculosis patients, latently infected individuals and controls 44
Utilizzo di nuovi test immunologici nella diagnostica dell'infezione e malattia da M. tuberculosis 43
Enumerazione delle cellule dendritiche circolanti: parametro predittivo di risposta viro-immunologica alla terapia antiretrovirale 42
Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. 41
Ruolo prognostico degli anticorpi anti-R7V in pazienti HIV+ 38
Randomized prospective crossover study evaluating the performance of Quantiferon TB Gold In-Tube in patients undergoing anti-TNF alpha treatment for screening and monitoring of latent tuberculosis infection 38
Diagnosi rapida di infezione da Micobatteri atipici su campioni respiratori 37
Biomarkers for active tuberculosis (TB) infection: potential role of IFN-g-inducible protein 10 (IP-10)-based assay” 37
HORMONAL STATUS AND NATURAL IMMUNITY IN HIV INFECTED PATIENTS 37
“Detection of M. tuberculosis infection by Interferon-g Release Assays: a comparative study in HIV-infected patients and in immunosuppressed people candidates for anti-TNF-a therapy” 37
Interferon-γ release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response. 37
"Utilizzo del TDM nella gestione dei pazienti HIV+ in trattamento ARV" 36
“Studio cross-over prospettico randomizzato di confronto tra Quantiferon TB Gold e Test secondo Mantoux nei pazienti candidati al trattamento con farmaci biologici antagonisti del TNFα” . 36
Effect of Antituberculosis Treatment on Specific Interferon-γ T-Cell Responses. 36
Diagnosi immunologica dell'infezione da M. tuberculosis in pazienti pediatrici e HIV positivi: Quantiferon (QF)-TB Gold 36
“Campagne informative di prevenzione: l’esperienza dell’ANLAIDS Lazio con i ragazzi delle scuole medie superiori”. 36
Cellule Dendritiche Plasmocitoidi: nuovo marker predittivo di fallimento virologico in pazienti con infezione da HIV in trattamento antiretrovirale (ARV) 35
PHARMACOLOGICAL MODULATION OF APOPTOSIS OF PBMC BY DARUNAVIR AND MARAVIROC 35
Inhibitory activity of Melissa officinalis L. extract on Herpes simples virus type 2 replication 35
Mycobacterial INFgamma release variation during long- term treatment with TNF blockers: lack of correlation with clinical outcome. 35
THE PERFORMANCE OF INTERFERON-G RELEASE ASSAYS (IGRAS) FOR TB DETECTION IS IMPAIRED IN HIV LATE PRESENTATION 34
Diagnosi immunologica dell'infezione da M. tuberculosis in pazienti HIV positivi: Quantiferon (QF)-TB Gold”. 33
TLR7 Signaling and IFN-α Production by pDC: Potential Target for Immunotherapy. 31
Ruolo delle Cellule Dendritiche nel cancro superficiale della vescica trattato con BCG 31
Study of intracellular and immunomodulant effects of CCR5 Antagonist Maraviroc 31
Screening dell’infezione tubercolare latente con Quantiferon® TB Gold nei militari impiegati in teatri operativi ad alta endemia – Dati preliminari 31
Utilità clinica del QUANTIFERON –TB GOLD nel monitoraggio terapeutico in corso di tubercolosi 30
Tubercolosi polmonare ed extrapolmonare: ruolo delle cellule dendritiche circolanti e produzione di interferon-alfa 29
Effect in vitro of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages, and DC 29
“TLR7 signaling and IFN-a production by pDC: potential target for immunoterapy “ 28
Sieroprevalenza dell’infezione da HSV-2 in una popolazione non selezionata 27
Lower Circulating Plasmocytoid Dendritic Cells Are Predictive of Virologic and Immunologic Failure in HIV Suppressed Patients, regardless of CD4 Count 26
“Utility of QuantiFERON-TB Gold in-tube for Tuberculosis screening in Italian Air Force personel” 25
Down-regulation in vitro of Matrix Metalloproteinase-9 in Rat Astrocytes by CCR5 Antagonist Maraviroc: Potential Therapeutical Implication for HIV-associated Neurologic Disease 25
Valutazione del cxcl10/ip10 come biomarker alternativo in pazienti con TUBERCOLOSI attiva E TEST quantiferon-GOLD negativo 25
Il QUANTIFERON-TB GOLD come parametro predittivo di infezione tubercolare recidivante”. 25
Role of pDC and mDC assessement in the management of HIV infection during antiretroviral therapy” 25
In vitro downregulation of anti-myelin proteolitic activity by indinavir 24
Study of the Immunomodulant Effect of New Class of Antretroviral Drugs: Downregulation of Cell Migration by Maraviroc. 24
“IGRAs assay for the screening of latent TB infection in patients candidate for TNF-α antagonist” 24
Studio prospettico crossover randomizzato sulla performance del test Quantiferon TB Gold-In tube per lo screening e il monitoraggio di infezione tubercolare latente in pazienti candidati al trattamento con farmaci antagonisti del TNF 23
Prospective randomized crossover study on the performance of QuantiFERON®-TB Gold In-Tube test for screening and monitoring of latent tuberculosis infection across patients undergoing anti-TNF treatment 23
“In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells” 23
Interventi per la Prevenzione della Trasmissione Materno-Infantile (MTCT) di HIV al di fuori dei trials clinici nei Paesi a risorse limitate: l’esperienza del Progetto “Mingha”, 22
Utilizzo di nuovi test immunologici nella diagnostica dell'infezione da Myc. Tuberculosis 22
“Serological profile in identical twins discordant for multiple sclerosis” 21
Infezione da M. tuberculosis: applicazione clinica del test Quantiferon (QF)-TB Gold 21
Impatto della terapia antitubercolare sul rilascio di interferon-GAMMA al test QUANTIFERON-TB GOLD”. 21
Studio della risposta immune specifica e naturale nella diagnostica della tubercolosi extrapolmonare: descrizione di un caso clinico 20
Utilizzo di parametri immunologici nella gestione della TBC-HIV associata: descrizione di un caso clinico 20
Test immunologici nello screening di infezione da M. tuberculosis in pazienti hiv positivi 20
“Interferon-g release assay (IGRA) nello screening della tubercolosi latente nei pazienti candidati al trattamento con antagonisti del TNFα” 20
“Usefulness of interferon-gamma release assays for latent tuberculosis screening in patients candidate for TNF-g therapy” 20
Utilizzo del Quantiferon TB-Gold in una coorte di soggetti pediatrici e HIV positivi 17
Dynamics of specific IFN-g T-cell responses during antituberculous treatment” 16
Ruolo del DC/Count e del Quantiferon (QF)-TB Gold nella diagnosi immunologica di infezione da M. tuberculosis 16
Il QuantiFERON-TB Gold nel monitoraggio terapeutico dell’infezione tubercolare 16
“Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon” Antonelli. 15
“Role of Interferon-γ Release Assays (IGRAs) in HIV-Associated Tuberculosis: in Vitro and in Vivo Effect of Antituberculous Drugs” 15
Plasmocytoid Dendritic Cells count predicts subsequent virologic failure in antiretroviral (ARV) treated HIV + patients 14
Totale 4.244
Categoria #
all - tutte 13.466
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.466


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020393 0 0 0 0 0 0 144 77 64 58 29 21
2020/2021268 21 22 9 23 0 90 4 30 20 25 18 6
2021/2022853 2 59 59 18 122 17 12 87 100 81 99 197
2022/2023834 189 127 32 87 125 99 6 57 85 4 15 8
2023/2024368 25 46 23 18 26 67 2 28 4 45 28 56
2024/2025375 40 30 51 19 52 106 77 0 0 0 0 0
Totale 4.244